Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
8,589 total articles
Taysha's TSHA-102 Rett program is on a faster path to potential approval, with dosing completion expected by Q2 2026 and FDA alignment on manufacturing and BLA strategy. That shortened timeline raises upside if data and filing go smoothly — but leaves little margin for safety or manufacturing setbacks. This trade idea lays out a long entry and expl…
GE HealthCare plunged after a Q1 earnings miss and a PDx supplier disruption. The sell-off opens a chance to buy a high-quality medical-equipment and diagnostics leader at about $28.4B market cap, with reasonable valuation metrics (P/E ~15, EV/EBITDA ~10). This trade idea lays out a disciplined long: entry $62.00, stop $58.75, target $75.00, horizo…
IonQ has become the poster child for commercially viable quantum computing after hitting technical milestones and benefiting from government funding for the sector. The stock is richly valued at a $26.9B market cap, but momentum, shrinking days-to-cover and concrete catalysts create a tradable mid-term opportunity. This trade idea lays out an entry…
Root, a telematics-first auto insurer, has moved from loss-making growth to profitability and now trades at modest multiples (market cap ~$824M, EV ~$427M, P/E ~15). With ROE near 17%, improving underwriting and an active short interest, the stock is a tradable swing setup. This trade idea buys a tactical dip for mid-term upside while capping downs…
TeraWulf is trading near its 52-week high after a sustained rerating driven by data-center expansion and investor appetite for crypto miners pivoting to AI infrastructure. The company carries clear execution and valuation risks, but recent financing, conference visibility, and bullish technicals make a measured long position attractive. Entry, stop…
Geron is a commercial-stage biotech with a growing oncology drug franchise (RYTELO). After a strong 2025 launch year ($184M net product revenue) and guidance for $220-240M in 2026, the stock trades near its 52-week low despite improving fundamentals. Technicals show oversold conditions and heavy short interest, creating a setup for a re-rating if c…
GTx-104's STRIVE-ON Phase 3 data show meaningful improvement in tolerability and dose intensity versus oral nimodipine. With a market cap near $40M and roughly $14.5M in cash on the balance sheet, Grace Therapeutics presents a high-risk, asymmetric opportunity. This trade plan targets a mid-term re-rating if regulatory clarity or partnership chatte…
Paymentus combines strong transaction growth and improving profitability with a conservative balance sheet. At a $2.95B market cap and positive free cash flow, the stock looks like a candidate for re-rating if transaction volumes and margin expansion continue. This trade lays out a clear entry, stop and target for a long-term (180 trading days) dir…
<p>Nvidia sits at the intersection of public policy and product advantage: direct government support for sovereign AI initiatives and a growing CPU partnership ecosystem materially expand addressable markets for its GPUs and networking silicon. At $214.80 the stock reflects strong fundamentals but leaves room for appreciation if the company continu…
Red Cat (RCAT) has been executing M&A and product ramps that stitch together air, ground and maritime autonomy. With a market cap near $2.2B, an expanding product set (V7 surface vessel, wireless charging, distributed control) and positive sector-level policy tailwinds, the setup supports a tactical long. Entry $14.49, stop $11.50, target $18.78 - …
Patria (PAX) is trading near its 52-week low despite record 2025 fundraising, 24% FEAUM growth to $40.8 billion, and a $202.5 million Fee Related Earnings base. Recent bolt-on deals - Solis, RBR, WP Global - are accretive and tilt the mix toward higher-fee Credit and U.S. private equity. At $11.59, the stock factors in a pessimistic take on integra…
WildBrain is a small-cap content play whose mix of owned IP, distribution channels and licensing deals makes the next three months potentially high-impact. We outline a tactical long with an entry at $2.40, a target at $3.60 and a stop at $1.75, and explain the fundamental drivers, catalysts and risks that justify a measured exposure over the next …
Vertiv (VRT) is a leader in critical data-center infrastructure whose investor conference reinforced revenue visibility and the company's role in the AI-driven buildout. Fundamentals — $2.28B in free cash flow, 36.7% return on equity, and a $15B backlog highlighted by management — support a constructive stance. We rate VRT a buy with a disciplined …
Nebius (NBIS) is trading near $231 after a year of massive revenue acceleration and large customer commitments. The company's AI-focused cloud and data-center strategy, backed by multibillion-dollar deals and rapid capacity expansion, supports a high-conviction long trade: entry $230.00, target $450.00, stop loss $200.00, horizon long term (180 tra…
Riley Exploration Permian (REPX) offers a compelling risk-reward as a conventional oil and gas operator focused on the San Andres and Permian shelf. At $33.26, the stock trades at single-digit EV/EBITDA and a sub-12x P/E with a 4.7% yield and consistent free cash flow. For traders looking for a mid-term swing (45 trading days), a measured long with…
Viking is trading at fresh 52-week highs after a sustained recovery in travel demand and strong premium pricing. Fundamentals and technicals line up for further upside, but fuel costs, competitive entry into river cruising and elevated valuation warrant a disciplined entry and a defined stop. This trade proposes a long with an entry near the market…
Comfort Systems USA (FIX) has rallied into a consolidation phase after a blistering multi-year move driven by data-center HVAC demand. The company brings a $12.45 billion backlog, strong margins, and $1.38B in free cash flow to the table. Valuation is rich but supported by growth and a fortress balance sheet. This trade idea targets a mid-term rebo…
Alamos Gold (AGI) offers leveraged exposure to rising gold prices through stable production and growth optionality at high-grade assets. This trade idea establishes a defined-entry long with a clear stop and two staged targets keyed to a constructive near-term gold outlook and execution catalysts.
Kimbell Royalty Partners reported stronger-than-expected Q1 production, declared a $0.41 distribution, and is evaluating M&A while keeping net debt to EBITDA at ~1.6x. The recent Permian acquisition modestly increases oil exposure; the combination of an ~11% yield, steady free cash flow, and active acreage makes KRP a tactical swing buy. Entry $15.…
Canadian Solar is transitioning from a module-first company to a hybrid developer-manufacturer where battery energy storage systems (BESS) are driving better economics. The market is still pricing execution risk aggressively: market cap is $1.29B, price-to-book sits at 0.45 and the stock trades well below its 52-week high. For traders willing to ac…
Silicom (SILC) has already seen the boom-and-bust typical of networking-cycle names. Price action, technicals and short-volume behaviour suggest the market is still valuing a re-acceleration that hasn't materialized. For traders, that creates a defined mid-term short opportunity: entry near today's levels, a nearby stop above last week's swing high…
Repligen (RGEN) is showing a technical and fundamental recovery as bioprocessing demand accelerates, but the stock trades at premium multiples (P/E ~136, P/S ~9.2) that leave little margin for execution missteps. This is a swing trade idea: enter near current levels, limit downside with a firm stop, and take profits into a near-term catalyst window…
Vicor's mid-quarter guidance raise and Q1 metrics (revenue $113M, 55.2% gross margins, $301M backlog) crystallize an IP-driven, high-margin growth story exposed to AI and data-center spend. The stock is richly valued but momentum, backlog and licensing cash flow create a favorable risk/reward for a mid-term swing. Enter with a clear stop and define…
Microsoft's share price reflects expectations of perpetual multiple expansion and flawless AI monetization. We see a near-term pullback risk driven by stretched sentiment and limited incremental margin upside. Here is a mid-term short trade with clear entry, stop and target, plus catalysts and risk controls.
Intellia has been grinding forward: clinical holds lifted, fresh capital on the balance sheet, and improving technicals. With market cap under $2.0B and $1.76B in cash, a binary path to first commercial approval creates asymmetry for a mid-term swing trade. This idea lays out an entry, stop, targets, and the risks to watch.
